Barinthus Biotherapeutics plc. (BRNS): restructuring charge — Barinthus Bio restructures: cuts 65% workforce, shifts focus to celiac VTP-1000

Barinthus Biotherapeutics plc.

Workforce reduction of ~65%; plans to close UK site, consolidate operations in Germantown, MD.
CFO Gemma Brown (departing April 30, 2025) and COO Graham Griffiths (June 30, 2025) to leave; severance agreements anticipated.
Prioritizes VTP-1000 (celiac disease) with Phase 1 data expected mid-2025; postpones VTP-300 hepatitis B development until partner found.
Preliminary cash, cash equivalents and restricted cash of $112M as of Dec 31, 2024; cash runway extended to start 2027.
Key 2025 milestones: VTP-1000 SAD data mid-2025; HBV003 and IM-PROVE II results in Q2 2025; VTP-850 prostate cancer data Q2 2025.

item 2.02 item 2.05 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Gemma Brown

Chief Financial Officer

BRNS · Barinthus Biotherapeutics plc.

Effective: 2025-04-30
Filed: January 10, 2025, 6:59 PM ET

the employment of Gemma Brown effective as of April 30, 2025

Departed

Graham Griffiths

Chief Operating Officer

BRNS · Barinthus Biotherapeutics plc.

Effective: 2025-06-30
Filed: January 10, 2025, 6:59 PM ET

the Company will terminate the employment of Graham Griffiths effective as of June 30, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gemma Brown was terminated as Chief Financial Officer at Barinthus Biotherapeutics plc..

Action: terminated
Role: Chief Financial Officer

Exact text from the filing

the employment of Gemma Brown effective as of April 30, 2025

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Graham Griffiths was terminated as Chief Operating Officer at Barinthus Biotherapeutics plc..

Action: terminated
Role: Chief Operating Officer

Exact text from the filing

the Company will terminate the employment of Graham Griffiths effective as of June 30, 2025

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Barinthus Biotherapeutics plc. announced a restructuring with charges of in the region of $2.5 million affecting UK (65% reduction in workforce).

Type: restructuring
Charge: in the region of $2.5 million
Affected area: UK
Headcount: 65% reduction in workforce

Exact text from the filing

On January 10, 2025, the Company announced a restructuring plan that aims to prioritize its immune tolerance research and development programs. The Company is planning a 65% reduction in workforce, which is subject to consultation with employee representatives in the UK regarding the plan. The Company anticipates that the majority of the reduction in workforce will occur in the UK and be completed during the first half of 2025. The Company estimates that the pre-tax costs of such reduction in workforce relating to employee severance and other employee-related costs may be in the region of $2.5 million with the majority of such costs being incurred in the first half of 2025.

View on SEC.gov

Browse all restructurings & charges →

Barinthus Biotherapeutics plc. filing history →

Source: SEC EDGAR

accession 0001828185-25-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.